Bold approaches to treat and cure genetic diseases

Emugen Therapeutics LLC is a discovery research company developing revolutionary treatments for patients with genetic disorders

ABOUT

Vision

Breakthrough discovery to accelerate therapeutic development:

Emugen Therapeutics LLC is a discovery research company developing revolutionary treatments for patients with genetic disorders. At Emugen, our team is leveraging novel genetic and chemogenetic technologies to develop safe and effective gene therapies for genetic disorders.

Approach

Collaborative, innovative, and risk-taking research:

Brain disorders are a leading contributor to the global burden of disease, yet there are no effective treatments for millions of patients living with neurological and psychiatric disorders. A major obstacle to progress in developing therapeutics has been the failure of translating treatments successfully developed in mice to successful human clinical trials. To address this considerable unmet need, Emugen’s innovative discovery engine is leveraging our founders’ world-renowned expertise in brain science, genetic engineering, animal models, gene therapy and brain disorders to advance a novel pipeline of gene therapies for clinical applications.

Platform

Empowering Emugen's discovery engine:

Emugen is building the industry’s most comprehensive pre-clinical research model development, genetic engineering techonologies, and testing platform--providing in-house support to our internal discovery engine and partnerships/services to pharma, biotech, and non-profit clients (including, but not limited to, genome editing in multiple models, biomarker studies, gene therapy efficacy and safety studies, and behavioral, cognitive, and neurophysiological testing).

Diversity

An inclusive research community:

Emugen is an equal-opportunity employer committed to promoting diversity, equity, and inclusion in both our workplace and our community. We maintain a collaborative and supportive environment where our employees’ voices are heard, and their opinions are valued.

Our Founders

Guoping Feng, Ph.D.

Guoping Feng is the Poitras Professor of Neuroscience and Associate Director of the McGovern Institute for Brain Research at MIT. Feng is also the Director of Model Systems and Neurobiology in the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard. Originally from Zhejiang Province in China, he received his PhD from SUNY Buffalo and postdoctoral training at Washington University at St. Louis. Before moving to MIT, he was a faculty member at Duke University. He is a member of the American Academy of Arts and Sciences and a recipient of numerous awards for his research accomplishments in neuroscience and brain disorder research.

Robert Desimone, Ph.D.

Robert Desimone is director of the McGovern Institute for Brain Research and the Doris and Don Berkey Professor of Neuroscience at MIT. Prior to joining the McGovern Institute in 2004, he was director of the Intramural Research Program at the National Institutes of Mental Health, the largest mental health research center in the world. He received his Ph.D. from Princeton University. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences and a recipient of numerous awards, including the Gerard Prize, the top award of the Society for Neuroscience.

Steven E. Hyman, M.D.

Steven E. Hyman is director of the Stanley Center for Psychiatric Research at Broad Institute of MIT and Harvard and Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology. Before that, Hyman served as provost of Harvard University from 2001 to 2011. He was also the director of the U.S. National Institute of Mental Health (NIMH), where he emphasized investment in neuroscience and genetic technologies.

JOIN US

Join Us

No openings right now, check back in later!

CONTACT